BioVie highlights Bezisterim Phase II data, eyes FDA path for Phase III trials

BioVie highlighted Phase II data for its drug Bezisterim and said it is pursuing an FDA path toward Phase III trials. The company framed the data as supporting further late-stage development of the candidate.

Detected & updated continuously · Source: Nebula